This article is more than 5 years old. Information may no longer be current.

SightLife Surgical to bring potential corneal blindness treatment to US

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SightLife Surgical plans to market a treatment for corneal blindness that involves culturing donated human eye endothelial cells and injecting them into the anterior chamber of a patient’s eye, the organization announced in a press release.

The innovative treatment has shown “promising” results in Japanese trials in which more than 30 patients have been treated over the past 2 years.

Injected cells safely restore sight to the patient within a month, the release said, and one donated human cornea can result in treatment for more than 100 patients.

Japanese trials have been conducted under Shigeru Kinoshita, MD, PhD, at Kyoto Prefectural University of Medicine, who will be working with SightLife Surgical to bring the cell processing capabilities to SightLife Surgical in Seattle.